Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cassava Sciences Inc SAVA

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

NDAQ:SAVA - Post Discussion

Cassava Sciences Inc > $SAVA - Watching This One Closely, Big Volatility Ahead!
View:
Post by ProfitGrid8448 on Nov 26, 2024 9:32am

$SAVA - Watching This One Closely, Big Volatility Ahead!

Yo, anyone else keeping an eye on $SAVA right now? It's been a rollercoaster, man. This thing is like the ultimate case study for biotech risk vs. reward. Last few weeks have been nuts — one minute we’re seeing a mini-rally based on some positive trial talk, then BOOM, another short-seller article drops and the thing tanks 10% in a day.I’m holding a small position right now. Not gonna lie, I like the story here long-term if Simufilam gets over the regulatory hurdles. The Alzheimer's space is massive, and if this drug actually works, it could be a game-changer. But the thing is, with biotech, there’s always a risk of a pump and dump. The stock price reacts like a pendulum — huge swings with any little update, whether it's positive or negative.The big question now is whether the FDA is gonna give this thing a green light or if they’ll slow it down with more trials. That Type C meeting they had was key, and I think there’s potential here if they can get past the scrutiny and prove their data’s solid.In the short-term, you gotta play this one like a swing trade — patience is key, but so is timing. If you’re not in yet, I’d wait for a dip, maybe after another "data release scare" or something. If it hits sub-$20 again, I might even add more shares. But this is not for the faint of heart, so don’t put your whole portfolio into it. Also, while I’ve been focusing on $SAVA, I’m keeping an eye on $BOLT too. Word on the street is that it’s setting up for a big move. People are talking about it possibly popping off soon, so I’m watching it closely for any signs of momentum.Anyone else trading $SAVA or thinking about it? Would love to hear other thoughts on the FDA timeline.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities